ImmunoGen, Inc.
NASDAQ:IMGN
Overview | Financials
Company Name | ImmunoGen, Inc. |
Symbol | IMGN |
Currency | USD |
Price | 31.235 |
Market Cap | 8,725,621,690 |
Dividend Yield | 0% |
52-week-range | 3.61 - 31.25 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Mark Joseph Enyedy |
Website | https://www.immunogen.com |
An error occurred while fetching data.
About ImmunoGen, Inc.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD